ClinicalTrials.gg
CompletedNCT02105987Updated Jan 4, 2017Results posted

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

A Phase 3 interventional study of ABC/DTG/3TC FDC and Ongoing cART regimen in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 103 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-04.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
555
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a 48-week, Phase IIIb, randomly assigned, open-label, active-controlled, multicenter, parallel group, non-inferiority study. This study is designed to demonstrate the non-inferior antiviral activity of switching to the Abacavir (ABC) 600 milligrams (mg)/Dolutegravir(DTG) 50 mg/Lamivudine (3TC) 300 mg fixed-dose combination (FDC) compared with continuing the subject's current suppressive regimen through 24 weeks. The study will be conducted in approximately 538 Human Immunodeficiency Virus -1 (HIV-1) infected individuals who are on stable suppressive combination antiretroviral therapy (cART) with 2 Nucleoside reverse transcriptase inhibitors (NRTIs) plus either a protease inhibitor (PI), an non-nucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor (INI). Eligible subjects will be randomly assigned 1:1 to continue their current regimen (approximately 269 subjects) or be switched to ABC/DTG/3TC FDC (approximately 269 subjects) once daily for 24 weeks. At Week 24, individuals originally randomly assigned to continue their current regimen will switch to ABC/DTG/3TC FDC and be followed for an additional 24 weeks. Individuals initially randomly assigned to ABC/DTG/3TC FDC will continue on that treatment arm for an additional 24 weeks. A pharmacokinetic (PK) substudy will be conducted at a small number of sites (approximately 10) to evaluate predose DTG concentrations as well as residual drug concentrations of efavirenz (EFV), nevaripine (NVP), amprenavir (APV) and tipranavir (TPV) in a subgroup of subjects who switch from EFV, NVP, fosamprenavir/ritonavir (FPV/r) or tipranavir/ritonavir (TPV/r).

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • Abacavir/dolutegravir/lamivudine
  • Fixed-dose combination
  • Once daily
  • Trii
  • Single-tablet regimen
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 555 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Be able to understand and comply with protocol requirements, instructions, and restrictions;
  • Be likely to complete the study as planned;
  • Be considered appropriate candidates for participation in an investigative clinical trial with oral medication (e.g., no active substance abuse, acute major organ disease, or planned long-term work assignments out of the country, etc.).
  • Signed and dated written is obtained from the subject or the subject's legal representative prior to screening
  • -1 infected men or women >=18 years of age;
  • A female may be eligible to enter and participate in the study if she: a. Is of non- either defined as (12 months of spontaneous amenorrhea and >=45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy or,
  • A female may be eligible to enter and participate in the study if she: b. Is of childbearing potential with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the following methods of to avoid pregnancy: Complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for at least 2 weeks after discontinuation of all study drugs; Double barrier method (e.g., male condom/spermicide, male condom/diaphragm, diaphragm/spermicide); Any intrauterine device (IUD) with published data showing that the expected failure rate is \<1% per year ; Male partner sterilization prior to the female subject's entry into the study and this male is the sole partner for that subject; Approved hormonal contraception for subjects randomly assigned to the ABC/DTG/3TC arm or approved hormonal contraception plus a barrier method for subjects assigned to continued antiretroviral therapy arm; Any other method with published data showing that the expected failure rate is \<1% per year.
  • Any contraception method must be used consistently, in accordance with the approved product label and for at least 2 weeks after discontinuation of study drug. A childbearing potential female subject who starts the study using complete abstinence as her contraceptive method and decides to become sexually active must use the double barrier method either as a bridge to an approved hormonal contraception (if possible) or as a method of choice to be maintained from that moment onwards.
  • All subjects participating in the study should be counselled on safer sexual practices including the use of effective barrier methods (e.g., male condom/spermicide).
  • Within the last year, 2 consecutive plasma HIV-1 Ribonucleic acid (RNA) measurements \<50 copies/millilitres (c/mL) and plasma HIV-1 RNA\<50 c/mL at Screening (\<75 b Deoxyribonucleic acid [bDNA] is considered equal to \<50 c/mL); Subjects who present at initial screening with a viral load between 50 to 200 c/mL can be retested once within the screening period.
  • Must be on current regimen (whether first or Combination antiretroviral therapy [cART]) for at least 6 months prior to Screening;
  • Acceptable stable cART regimens prior to Screening include: • Boosted PI (or Atazanavir [ATV]) unboosted) + 2 NRTIs, NNRTI + 2 NRTIs, • INI + 2 NRTIs. For subjects on an INI, their INI at Screening must be RAL or Elvitegravir (EVG)
  • Any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability and/or safety concerns.
  • Subject must have achieved plasma HIV-1 RNA level \<50 c/mL within 6 months of start of initial cART regimen with no plasma HIV-1 RNA level >200 c/mL following initial suppression;
  • Documentation that the subject is negative for the human leukocyte antigen (HLA) B*5701 allele;

Exclusion Criteria:

Exclusionary Medical Conditions

  • Women who are breastfeeding;
  • Any evidence of an active (Centers for Disease Control and Prevention [CDC] Category C) disease. Exceptions include cutaneous Kaposi's sarcoma not requiring systemic therapy and historic of \<200 cells/cubic millimeter (mm).
  • Subjects with any degree of hepatic impairment;
  • Subjects positive for virus surface antigen (+HBsAg) at Screening or with an anticipated need for virus (HCV) therapy during the study;
  • History or presence of allergy to the study drugs or their components or drugs of their class;
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the study medical monitor for inclusion of the subject;
  • Subjects who, in the investigator's judgment, pose a significant suicidality risk. Recent history of suicidal behavior and/or suicidal ideation may be considered as evidence of serious suicide risk;

Exclusionary Treatments Prior to Screening or Day 1

  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening;
  • Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any immunomodulators that alter immune responses;
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study drug;
  • A history of use of only mono or dual NRTI therapy prior to starting cART;
  • Use of etravirine at time of switch;
  • Use of DTG at time of switch;
  • Subjects receiving any prohibited medication listed in the protocol and who are unwilling or unable to switch to an alternate medication

Exclusionary Laboratory Values or Clinical Assessments at Screening

  • Evidence of primary viral resistance based on the presence of any resistance-associated major PI or any NRTI, NNRTI, or INI mutation in any prior resistance genotype assay result;
  • Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 triglyceride abnormalities. A single repeat test is allowed during the screening period to verify a result;
  • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the subject's participation in the study of an compound;
  • (ALT) >=5 times the (ULN), or ALT >=3 × ULN and >=1.5 × ULN (with >35% direct bilirubin);
  • Subject has of \<50 mL/min using Modification of Diet in Renal Disease ();
  • (Bazett) >=450 msec or QTc (Bazett) >=480 msec for subjects with bundle branch block. The QTc is the QT interval corrected for heart rate according to Bazett's formula (QTcB). The QTc should be based on a single QTc value (ECG) obtained.
  • Eligibility of subjects for study participation will be decided by the investigators after taking into consideration various country specific guidelines, and notwithstanding the above mentioned minimum inclusion and exclusion criteria.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
555 participants (actual)

Study arms

  • Experimental
    ABC/DTG/3TC

    Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.

    Drug: ABC/DTG/3TC FDC

  • Active comparator
    Comparator

    Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.

    Drug: Ongoing cART regimen

Interventions

  • DrugABC/DTG/3TC FDC

    Drug pages: Dolutegravir · Lamivudine

    Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC

  • DrugOngoing cART regimen

    Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs

06

What researchers measure

Primary outcomes

  1. Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 24 Using the Snapshot Algorithm

    The Food and Drug Administration (FDA) snapshot (Missing, Switch or Discontinuation = Failure) algorithm is intended to be primarily a virologic assessment of the endpoint, and as such follows a "virology first" hierarchy. Virologic Success (e.g., \<50 c/mL) or virologic failure within an analysis window is typically determined by the last available HIV-1 RNA measurement in that window and in the treatment phase of interest (e.g., Week 24 snapshot outcomes of the early switch phase will not use HIV-1 RNA data from the late switch phase, even if such data is within the Week 24 analysis window). A virologic failure occurs when a participant changes to their ART regimen (e.g., addition of other ARTs to the study-specified regimens, or switches in components of the current ART regimen).

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 24

    Change from Baseline in CD4+ cell counts were assessed at Baseline, Weeks 4, 8, 16 and 24. No imputation for missing data or premature discontinuation was performed and the observed values were used. Baseline value is defined as the last pre-treatment value observed. Change from Baseline was calculated as the observed value minus the Baseline value. The Week 24 data were summarized.

    Time frame: Baseline and Week 24

  2. Number of Participants in the Virologic Non-response Category From the Snapshot Analysis at Week 24

    Virologic non-responders were defined as the participants with a viral load \>=50 c/mL in the Week 24 analysis window. Virologic non-response includes participants who had HIV-1 RNA \>=50 c/mL, who discontinued for lack of efficacy, who discontinued for other reasons while not suppressed, data in window but not \<50 c/mL, and who changed ART regimen at Week 24. Difference is calculated as the proportion on ABC/DTG/3TC - proportion on current ART regimen.

    Time frame: Week 24

  3. Number of Participants With Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 24 Weeks

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgment and all events of possible drug-induced liver injury with hyperbilirubinemia. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS estimates the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.

    Time frame: Baseline and up to 24 weeks

  4. Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to 24 Weeks

    The number of participants with maximum post-Baseline emergent chemistry toxicities for each grade were summarized by parameter. A toxicity is considered emergent if it develops or increases in intensity from Baseline. For participants who were originally randomized to current ART regimen on Day 1 and then switched to ABC/DTG/3TC on Week 24, Baseline is defined as the last non-missing value from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.

    Time frame: Baseline and up to 24 weeks

  5. Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to 24 Weeks

    The number of participants with maximum post-Baseline emergent hematology toxicities for each grade were summarized by parameter. A toxicity is considered emergent if it develops or increases in intensity from Baseline. For participants who were originally randomized to current ART regimen on Day 1 and then switched to ABC/DTG/3TC on Week 24, Baseline is defined as the last non-missing value from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.

    Time frame: Baseline and up to 24 weeks

  6. Number of Participants With AEs Leading to Withdrawal Over 24 Weeks

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgment and all events of possible drug-induced liver injury with hyperbilirubinemia.

    Time frame: Baseline and up to 24 weeks

  7. Change From Baseline in Fasting Lipids (Cholesterol, LDL Cholesterol, HDL Cholesterol, and Triglycerides) at Week 24

    Change from Baseline for each fasting lipid parameters included cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Adjusted mean is the estimated mean change from Baseline in each parameter at Week 24 in each arm calculated from an analysis of covariance (ANCOVA) model which includes the following covariates: treatment, original ART third agent class, interaction of treatment and original ART 3rd agent, use of lipid modifying agent and Baseline lipid level. Difference is calculated as ABC/DTG/3TC - Current ART regimen. For fasting lipid assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast was acceptable for participants with afternoon appointments.

    Time frame: Baseline and Week 24

  8. Change From Baseline in Fasting Lipids (Total Cholesterol/HDL Cholesterol Ratio) at Week 24

    Change from Baseline for fasting lipid parameter total cholesterol/HDL cholesterol ratio. Adjusted mean is the estimated mean change from Baseline at Week 24 in each arm calculated from an analysis of covariance (ANCOVA) model which includes the following covariates: treatment, original ART third agent class, interaction of treatment and original ART 3rd agent, use of lipid modifying agent and Baseline lipid level. Difference is calculated as ABC/DTG/3TC - Current ART regimen. For fasting lipid assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast was acceptable for participants with afternoon appointments.

    Time frame: Baseline and Week 24

  9. Change From Baseline in Treatment Satisfaction at Week 4 and Week 24

    The HIV treatment satisfaction questionnaire (TSQ) is a 10 item self-reported scale. Individual item scores range from 6 (very satisfied) to 0 (very dissatisfied). The treatment satisfaction total score (range 0-60) is the sum of all the 10 individual items. The general satisfaction/Clinical subscale (range 0-30) is the sum of the 5 clinical items and the lifestyle/ease subscale (range 0-30) is the sum of the remaining 5 lifestyle items. Last observation carried forward (LOCF) were used for the analysis. If a participant had a missing value at Week 24, his previous non-missing available value while on the same treatment was carried forward (ie the Week 4 or withdrawal value is used in the Week 24 summary for participants in the ABC/DTG3TC with missing Week 24 value). Data were analyzed using an ANCOVA model with factors including treatment, Baseline score and stratification factor. Treatment group difference (ABC/DTG/3TC-cART) estimate and 95% CI were presented.

    Time frame: Baseline, Week 4 and Week 24

  10. Change From Baseline in Creatinine at Week 24

    Renal markers included creatinine and summarized based on an observed case (OC) data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

    Time frame: Baseline and Week 24

  11. Change From Baseline in Glomerular Filtration Rate (GFR) From Creatinine Adjusted Using CKD-EPI Equation at Week 24

    Renal markers included GFR from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI) equation and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

    Time frame: Baseline and Week 24

  12. Change From Baseline in GFR From Creatinine Adjusted Using MDRD Enzymatic Equation at Week 24

    Renal markers included GFR from creatinine adjusted using modification of diet in renal disease (MDRD) enzymatic equation and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

    Time frame: Baseline and Week 24

  13. Change From Baseline in Urea at Week 24

    Renal markers included urea and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

    Time frame: Baseline and Week 24

  14. Change From Baseline in Urine Albumin/Creatinine Ratio at Week 24

    Renal markers included urine albumin/creatinine ratioand summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

    Time frame: Baseline and Week 24

  15. Percent Change From Baseline in Bone Marker Analytes at Week 24

    Outcome Measure Description: Bone biomarkers analytes include bone specific alkaline phosphatase, osteocalcin, procollagen 1 n-terminal propeptide, type I collagen c-telopeptides and were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, age, sex (male or female), body mass index (BMI) (\<25 kilogram per meter \[kg/m\] or \>=25 kg/m), smoking status (never smoked or former smoker or current smoker), Baseline vitamin D (no vitamin D use at Baseline or vitamin D use at Baseline), and Baseline biomarker level.

    Time frame: Baseline and Week 24

  16. Percent Change From Baseline in Cardiovascular Marker Analytes at Week 24

    Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.

    Time frame: Baseline and Week 24

  17. Percent Change From Baseline in Cardiovascular Marker Analyte, C-reactive Protein at Week 24

    Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.

    Time frame: Baseline and Week 24

  18. Percent Change From Baseline in Cardiovascular Marker Analyte, D-Dimer at Week 24

    Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.

    Time frame: Baseline and Week 24

  19. Percent Change From Baseline in Cardiovascular Marker Analyte, Homostat Model Assess of Insulin Resistance at Week 24

    Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.

    Time frame: Baseline and Week 24

  20. Percent Change From Baseline in Cardiovascular Marker Analyte, Insulin at Week 24

    Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.

    Time frame: Baseline and Week 24

  21. Percent Change From Baseline in Cardiovascular Marker Analyte, Soluble CD163 at Week 24

    Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.

    Time frame: Baseline and Week 24

  22. Percent Change From Baseline in Cardiovascular Marker Analyte, Glucose at Week 24

    Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.

    Time frame: Baseline and Week 24

  23. Number of Participants With Incidence of Genotypic and Phenotypic Resistance Meeting Confirmed Virologic Withdrawal Criteria Over 24 Weeks

    Genotypic and phenotypic testing was conducted for participants who met the confirmed virologic withdrawal criteria, i.e., confirmed HIV-1 RNA \>=400 c/mL any time after Day 1. The sample from the "suspected virologic withdrawal criterion" visit was tested for HIV-1 PRO and RT genotype and phenotype and HIV-1 integrase genotype and phenotype (i.e., the first of the two consecutive results \>=400 c/mL). At the time of the data cut-off for this Week 24 analysis, no participants met the confirmed virologic withdrawal criteria over 24 weeks; therefore, the virologic analyses were not assessed.

    Time frame: Baseline and up to 24 weeks

07

Results

Posted Feb 25, 2016

Participant flow

Early Switch Phase (24 Weeks)
Participant flow — Early Switch Phase (24 Weeks)
MilestoneABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ARTABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early SwitchABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late SwitchABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch:Cont PhaseABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch:Cont Phase
Started2752780000
Completed2392440000
Not completed36340000
Withdrew: Adverse event1000000
Withdrew: Protocol violation15170000
Withdrew: Withdrawal by subject4100000
Withdrew: Lost to follow-up330000
Withdrew: Physician decision430000
Withdrew: Missing disposition data010000
Late Switch Phase (24 Weeks)
Participant flow — Late Switch Phase (24 Weeks)
MilestoneABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ARTABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early SwitchABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late SwitchABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch:Cont PhaseABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch:Cont Phase
Started0027524400
Completed0023023000
Not completed00451400
Withdrew: Adverse event0010400
Withdrew: Protocol violation0015100
Withdrew: Withdrawal by subject006500
Withdrew: Lost to follow-up008300
Withdrew: Physician decision005000
Withdrew: Met protocol defined stopping criteria000100
Withdrew: Per sponsor request001000
Continuation Phase
Participant flow — Continuation Phase
MilestoneABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ARTABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early SwitchABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late SwitchABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch:Cont PhaseABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch:Cont Phase
Started00001423
Completed00001323
Not completed000010
Withdrew: Protocol violation000010

Outcome measures

PrimaryNumber of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 24 Using the Snapshot Algorithm

The Food and Drug Administration (FDA) snapshot (Missing, Switch or Discontinuation = Failure) algorithm is intended to be primarily a virologic assessment of the endpoint, and as such follows a "virology first" hierarchy. Virologic Success (e.g., \<50 c/mL) or virologic failure within an analysis window is typically determined by the last available HIV-1 RNA measurement in that window and in the treatment phase of interest (e.g., Week 24 snapshot outcomes of the early switch phase will not use HIV-1 RNA data from the late switch phase, even if such data is within the Week 24 analysis window). A virologic failure occurs when a participant changes to their ART regimen (e.g., addition of other ARTs to the study-specified regimens, or switches in components of the current ART regimen).

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 24 Using the Snapshot Algorithm
ParticipantsABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 24 Using the Snapshot Algorithm233245
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · Cochran-Mantel-Haenszel · Mean difference (net): -3.4 · 95% CI -9.1 to 2.4Based on Cochran-Mantel Haenszel stratified analysis adjusting for the following Baseline stratification factor: Original ART third agent class (PI, NNRTI, or INI).
SecondaryChange From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 24

Change from Baseline in CD4+ cell counts were assessed at Baseline, Weeks 4, 8, 16 and 24. No imputation for missing data or premature discontinuation was performed and the observed values were used. Baseline value is defined as the last pre-treatment value observed. Change from Baseline was calculated as the observed value minus the Baseline value. The Week 24 data were summarized.

Time frame:
Baseline and Week 24
Reported as:
Median · Cells per cubic millimeter (cells/mm^3)
Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 24
Cells per cubic millimeter (cells/mm^3)ABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 2450.0 (-48.0 to 130.0)11.0 (-60.0 to 103.5)
SecondaryNumber of Participants in the Virologic Non-response Category From the Snapshot Analysis at Week 24

Virologic non-responders were defined as the participants with a viral load \>=50 c/mL in the Week 24 analysis window. Virologic non-response includes participants who had HIV-1 RNA \>=50 c/mL, who discontinued for lack of efficacy, who discontinued for other reasons while not suppressed, data in window but not \<50 c/mL, and who changed ART regimen at Week 24. Difference is calculated as the proportion on ABC/DTG/3TC - proportion on current ART regimen.

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants in the Virologic Non-response Category From the Snapshot Analysis at Week 24
ParticipantsABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Number of Participants in the Virologic Non-response Category From the Snapshot Analysis at Week 2434
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · Cochran-Mantel-Haenszel · Mean difference (net): -0.3 · 95% CI -2.0 to 1.4Based on Cochran-Mantel Haenszel stratified analysis adjusting for the following Baseline stratification factor: Original ART third agent class (PI, NNRTI, or INI).
SecondaryNumber of Participants With Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 24 Weeks

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgment and all events of possible drug-induced liver injury with hyperbilirubinemia. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS estimates the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.

Time frame:
Baseline and up to 24 weeks
Reported as:
Number · Participants
Number of Participants With Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 24 Weeks
ParticipantsABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Any AEs183129
Any SAEs65
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to 24 Weeks

The number of participants with maximum post-Baseline emergent chemistry toxicities for each grade were summarized by parameter. A toxicity is considered emergent if it develops or increases in intensity from Baseline. For participants who were originally randomized to current ART regimen on Day 1 and then switched to ABC/DTG/3TC on Week 24, Baseline is defined as the last non-missing value from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.

Time frame:
Baseline and up to 24 weeks
Reported as:
Number · Participants
Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to 24 Weeks
ParticipantsABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Grade 198108
Grade 27371
Grade 32125
Grade 41010
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to 24 Weeks

The number of participants with maximum post-Baseline emergent hematology toxicities for each grade were summarized by parameter. A toxicity is considered emergent if it develops or increases in intensity from Baseline. For participants who were originally randomized to current ART regimen on Day 1 and then switched to ABC/DTG/3TC on Week 24, Baseline is defined as the last non-missing value from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.

Time frame:
Baseline and up to 24 weeks
Reported as:
Number · Participants
Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to 24 Weeks
ParticipantsABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Grade 11915
Grade 236
Grade 302
Grade 410
SecondaryNumber of Participants With AEs Leading to Withdrawal Over 24 Weeks

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgment and all events of possible drug-induced liver injury with hyperbilirubinemia.

Time frame:
Baseline and up to 24 weeks
Reported as:
Number · Participants
Number of Participants With AEs Leading to Withdrawal Over 24 Weeks
ParticipantsABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Number of Participants With AEs Leading to Withdrawal Over 24 Weeks110
SecondaryChange From Baseline in Fasting Lipids (Cholesterol, LDL Cholesterol, HDL Cholesterol, and Triglycerides) at Week 24

Change from Baseline for each fasting lipid parameters included cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Adjusted mean is the estimated mean change from Baseline in each parameter at Week 24 in each arm calculated from an analysis of covariance (ANCOVA) model which includes the following covariates: treatment, original ART third agent class, interaction of treatment and original ART 3rd agent, use of lipid modifying agent and Baseline lipid level. Difference is calculated as ABC/DTG/3TC - Current ART regimen. For fasting lipid assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast was acceptable for participants with afternoon appointments.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Change From Baseline in Fasting Lipids (Cholesterol, LDL Cholesterol, HDL Cholesterol, and Triglycerides) at Week 24
Millimoles per liter (mmol/L)ABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Cholesterol,n=226, 2310.10 (0.00 to 0.21)-0.01 (-0.11 to 0.10)
LDL Cholesterol, n=221, 2260.10 (0.01 to 0.18)0.02 (-0.06 to 0.11)
HDL Cholesterol, n=226, 2310.00 (-0.04 to 0.03)-0.03 (-0.06 to 0.01)
Triglycerides, n=226, 2310.07 (-0.07 to 0.21)-0.04 (-0.17 to 0.10)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.096 · Mean difference (final values): 0.11 · 95% CI -0.02 to 0.23Statistical analysis of cholesterol is presented
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.167 · Median difference (final values): 0.07 · 95% CI -0.03 to 0.18Statistical analysis of LDL cholesterol is presented
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.317 · Median difference (final values): 0.02 · 95% CI -0.02 to 0.06Statistical analysis of HDL cholesterol is presented
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.187 · Mean difference (final values): 0.11 · 95% CI -0.05 to 0.27Statistical analysis of triglycerides is presented
SecondaryChange From Baseline in Fasting Lipids (Total Cholesterol/HDL Cholesterol Ratio) at Week 24

Change from Baseline for fasting lipid parameter total cholesterol/HDL cholesterol ratio. Adjusted mean is the estimated mean change from Baseline at Week 24 in each arm calculated from an analysis of covariance (ANCOVA) model which includes the following covariates: treatment, original ART third agent class, interaction of treatment and original ART 3rd agent, use of lipid modifying agent and Baseline lipid level. Difference is calculated as ABC/DTG/3TC - Current ART regimen. For fasting lipid assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast was acceptable for participants with afternoon appointments.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Ratio
Change From Baseline in Fasting Lipids (Total Cholesterol/HDL Cholesterol Ratio) at Week 24
RatioABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Change From Baseline in Fasting Lipids (Total Cholesterol/HDL Cholesterol Ratio) at Week 240.10 (-0.02 to 0.22)0.00 (-0.12 to 0.12)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.175 · Mean difference (final values): 0.10 · 95% CI -0.04 to 0.25Statistical analysis of total cholesterol/HDL cholesterol ratio is presented
SecondaryChange From Baseline in Treatment Satisfaction at Week 4 and Week 24

The HIV treatment satisfaction questionnaire (TSQ) is a 10 item self-reported scale. Individual item scores range from 6 (very satisfied) to 0 (very dissatisfied). The treatment satisfaction total score (range 0-60) is the sum of all the 10 individual items. The general satisfaction/Clinical subscale (range 0-30) is the sum of the 5 clinical items and the lifestyle/ease subscale (range 0-30) is the sum of the remaining 5 lifestyle items. Last observation carried forward (LOCF) were used for the analysis. If a participant had a missing value at Week 24, his previous non-missing available value while on the same treatment was carried forward (ie the Week 4 or withdrawal value is used in the Week 24 summary for participants in the ABC/DTG3TC with missing Week 24 value). Data were analyzed using an ANCOVA model with factors including treatment, Baseline score and stratification factor. Treatment group difference (ABC/DTG/3TC-cART) estimate and 95% CI were presented.

Time frame:
Baseline, Week 4 and Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Treatment Satisfaction at Week 4 and Week 24
Units on a scaleABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Total score, n=270,2763.2 ± 0.400.8 ± 0.39
General Satisfaction/Clinical Subscale, n=269, 2761.3 ± 0.240.2 ± 0.23
Lifestyle/Ease Subscale Score, n=269, 2761.8 ± 0.190.6 ± 0.19
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = <0.001 · Mean difference (net): 2.4 · 95% CI 1.3 to 3.5Statistical analysis for total score is presented
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.002 · Mean difference (net): 1.0 · 95% CI 0.4 to 1.7Statistical analysis for general satisfaction/clinical subscale score is presented
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = <0.001 · Mean difference (net): 1.3 · 95% CI 0.8 to 1.8Statistical analysis for lifestyle/ease subscale is presented
SecondaryChange From Baseline in Creatinine at Week 24

Renal markers included creatinine and summarized based on an observed case (OC) data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Micromoles per liter (umol/L)
Change From Baseline in Creatinine at Week 24
Micromoles per liter (umol/L)ABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Change From Baseline in Creatinine at Week 247.63 (6.46 to 8.80)1.12 (-0.03 to 2.27)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = <0.001 · Mean difference (final values): 6.51 · 95% CI 4.86 to 8.16
SecondaryChange From Baseline in Glomerular Filtration Rate (GFR) From Creatinine Adjusted Using CKD-EPI Equation at Week 24

Renal markers included GFR from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI) equation and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mL/second
Change From Baseline in Glomerular Filtration Rate (GFR) From Creatinine Adjusted Using CKD-EPI Equation at Week 24
mL/secondABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Change From Baseline in Glomerular Filtration Rate (GFR) From Creatinine Adjusted Using CKD-EPI Equation at Week 24-8.05 (-9.30 to -6.80)-1.18 (-2.41 to 0.06)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = <0.001 · Mean difference (final values): -6.87 · 95% CI -8.64 to -5.11
SecondaryChange From Baseline in GFR From Creatinine Adjusted Using MDRD Enzymatic Equation at Week 24

Renal markers included GFR from creatinine adjusted using modification of diet in renal disease (MDRD) enzymatic equation and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mL/second/1.73 meter square
Change From Baseline in GFR From Creatinine Adjusted Using MDRD Enzymatic Equation at Week 24
mL/second/1.73 meter squareABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Change From Baseline in GFR From Creatinine Adjusted Using MDRD Enzymatic Equation at Week 24-0.16 (-0.18 to -0.13)-0.02 (-0.04 to 0.00)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = <0.001 · Mean difference (final values): -0.13 · 95% CI -0.17 to -0.10
SecondaryChange From Baseline in Urea at Week 24

Renal markers included urea and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Change From Baseline in Urea at Week 24
Millimoles per liter (mmol/L)ABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Change From Baseline in Urea at Week 24-0.03 (-0.18 to 0.12)0.07 (-0.08 to 0.22)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.375 · Mean difference (final values): -0.10 · 95% CI -0.31 to 0.12
SecondaryChange From Baseline in Urine Albumin/Creatinine Ratio at Week 24

Renal markers included urine albumin/creatinine ratioand summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Gram per mole (G/mol) creatinine
Change From Baseline in Urine Albumin/Creatinine Ratio at Week 24
Gram per mole (G/mol) creatinineABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Change From Baseline in Urine Albumin/Creatinine Ratio at Week 240.11 (-0.70 to 0.92)-0.07 (-0.84 to 0.69)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.749 · Mean difference (final values): 0.18 · 95% CI -0.93 to 1.30
SecondaryPercent Change From Baseline in Bone Marker Analytes at Week 24

Outcome Measure Description: Bone biomarkers analytes include bone specific alkaline phosphatase, osteocalcin, procollagen 1 n-terminal propeptide, type I collagen c-telopeptides and were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, age, sex (male or female), body mass index (BMI) (\<25 kilogram per meter \[kg/m\] or \>=25 kg/m), smoking status (never smoked or former smoker or current smoker), Baseline vitamin D (no vitamin D use at Baseline or vitamin D use at Baseline), and Baseline biomarker level.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · Percent
Percent Change From Baseline in Bone Marker Analytes at Week 24
PercentABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Bone specific alkaline phosphatase, n= 214, 2240.84 (0.79 to 0.88)0.98 (0.93 to 1.03)
Osteocalcin, n=211, 2210.87 (0.82 to 0.93)0.96 (0.90 to 1.03)
Procollagen 1 n-terminal propeptide, n=212, 2220.88 (0.83 to 0.94)0.96 (0.91 to 1.03)
Type I collagen c-telopeptides, n=212, 2230.87 (0.79 to 0.95)1.03 (0.94 to 1.14)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = <0.001 (Bone specific alkaline phosphatase) · Geometric mean ratio: 0.86 · 95% CI 0.82 to 0.90
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.002 (Osteocalcin) · Geometric mean ratio: 0.91 · 95% CI 0.85 to 0.96
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.001 (Procollagen 1 n-terminal propeptide) · Geometric mean ratio: -0.09 · 95% CI -0.15 to -0.04
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.001 (Type I collagen c-telopeptides) · Geometric mean ratio: 0.91 · 95% CI 0.86 to 0.96
SecondaryPercent Change From Baseline in Cardiovascular Marker Analytes at Week 24

Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · Percent
Percent Change From Baseline in Cardiovascular Marker Analytes at Week 24
PercentABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Fatty acid binding protein 2 [ng/L], n=212,2220.67 (0.59 to 0.75)1.04 (0.92 to 1.17)
Interleukin 6 [ng/L], n=213,2220.86 (0.74 to 0.99)0.80 (0.69 to 0.92)
Soluble cd14 [ng/L], n=214,2230.76 (0.73 to 0.79)0.82 (0.79 to 0.85)
Soluble vasc cell adhesion mol 1[ng/L], n=213,2220.86 (0.80 to 0.92)0.85 (0.80 to 0.91)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = <0.001 (Fatty acid binding protein 2) · Geometric mean ratio: 0.64 · 95% CI 0.57 to 0.72
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.311 (Interleukin 6) · Geometric mean ratio: 1.08 · 95% CI 0.93 to 1.24
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = <0.001 (Soluble CD14) · Geometric mean ratio: 0.92 · 95% CI 0.89 to 0.96
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.742 (Soluble vasc cell adhesion molecule 1) · Geometric mean ratio: 1.01 · 95% CI 0.95 to 1.08
SecondaryPercent Change From Baseline in Cardiovascular Marker Analyte, C-reactive Protein at Week 24

Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · Percent
Percent Change From Baseline in Cardiovascular Marker Analyte, C-reactive Protein at Week 24
PercentABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Percent Change From Baseline in Cardiovascular Marker Analyte, C-reactive Protein at Week 241.25 (1.04 to 1.50)1.25 (1.04 to 1.49)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.999 · Geometric mean ratio: 1.00 · 95% CI 0.84 to 1.19
SecondaryPercent Change From Baseline in Cardiovascular Marker Analyte, D-Dimer at Week 24

Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · Percent
Percent Change From Baseline in Cardiovascular Marker Analyte, D-Dimer at Week 24
PercentABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Percent Change From Baseline in Cardiovascular Marker Analyte, D-Dimer at Week 241.00 (0.91 to 1.10)1.00 (0.91 to 1.10)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.981 · Geometric mean ratio: 1.00 · 95% CI 0.91 to 1.10
SecondaryPercent Change From Baseline in Cardiovascular Marker Analyte, Homostat Model Assess of Insulin Resistance at Week 24

Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · Percent
Percent Change From Baseline in Cardiovascular Marker Analyte, Homostat Model Assess of Insulin Resistance at Week 24
PercentABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Percent Change From Baseline in Cardiovascular Marker Analyte, Homostat Model Assess of Insulin Resistance at Week 240.97 (0.84 to 1.11)1.00 (0.87 to 1.14)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.640 · Geometric mean ratio: 0.97 · 95% CI 0.85 to 1.11
SecondaryPercent Change From Baseline in Cardiovascular Marker Analyte, Insulin at Week 24

Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · Percent
Percent Change From Baseline in Cardiovascular Marker Analyte, Insulin at Week 24
PercentABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Percent Change From Baseline in Cardiovascular Marker Analyte, Insulin at Week 240.97 (0.86 to 1.09)0.99 (0.88 to 1.12)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.645 · Geometric mean ratio: 0.97 · 95% CI 0.87 to 1.09
SecondaryPercent Change From Baseline in Cardiovascular Marker Analyte, Soluble CD163 at Week 24

Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · Percent
Percent Change From Baseline in Cardiovascular Marker Analyte, Soluble CD163 at Week 24
PercentABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Percent Change From Baseline in Cardiovascular Marker Analyte, Soluble CD163 at Week 241.09 (1.04 to 1.15)1.08 (1.02 to 1.13)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.577 · Geometric mean ratio: 1.01 · 95% CI 0.97 to 1.06
SecondaryPercent Change From Baseline in Cardiovascular Marker Analyte, Glucose at Week 24

Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · Percent
Percent Change From Baseline in Cardiovascular Marker Analyte, Glucose at Week 24
PercentABC 600 mg / DTG 50 mg /3TC 300 mg FDCCurrent ART
Percent Change From Baseline in Cardiovascular Marker Analyte, Glucose at Week 241.02 (0.99 to 1.05)1.01 (0.99 to 1.04)
Statistical analysis
  • ABC 600 mg / DTG 50 mg /3TC 300 mg FDC vs Current ART · ANCOVA · p = 0.687 · Geometric mean ratio: 1.01 · 95% CI 0.98 to 1.03
SecondaryNumber of Participants With Incidence of Genotypic and Phenotypic Resistance Meeting Confirmed Virologic Withdrawal Criteria Over 24 Weeks

Genotypic and phenotypic testing was conducted for participants who met the confirmed virologic withdrawal criteria, i.e., confirmed HIV-1 RNA \>=400 c/mL any time after Day 1. The sample from the "suspected virologic withdrawal criterion" visit was tested for HIV-1 PRO and RT genotype and phenotype and HIV-1 integrase genotype and phenotype (i.e., the first of the two consecutive results \>=400 c/mL). At the time of the data cut-off for this Week 24 analysis, no participants met the confirmed virologic withdrawal criteria over 24 weeks; therefore, the virologic analyses were not assessed.

Time frame:
Baseline and up to 24 weeks

No measurements were reported for this outcome.

Adverse events

Collected over Early Switch group AEs/SAEs are included from time of switch to ABC 600mg/DTG 50mg/3TC 300mg at baseline up to Week 48. Late Switch group AEs/SAEs are included from the time of switch to ABC 600mg/DTG 50mg/3TC 300mg at week 24 up to Week 48.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC—9/275 (3.3%)101/275 (36.7%)
Late Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC—6/244 (2.5%)61/244 (25%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventEarly Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDCLate Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC
Myocardial infarctionCardiac disorders0/2751/244
DiverticulitisInfections and infestations0/2751/244
Subcutaneous abscessInfections and infestations0/2751/244
Femur fractureInjury, poisoning and procedural complications0/2751/244
Alanine aminotransferase increasedInvestigations0/2751/244
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2751/244
Cardiac failure congestiveCardiac disorders1/2750/244
CellulitisInfections and infestations1/2750/244
GastroenteritisInfections and infestations1/2750/244
Pneumonia bacterialInfections and infestations1/2750/244
Most frequent other events
Most frequent other events
EventEarly Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDCLate Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC
Upper respiratory tract infectionInfections and infestations35/27522/244
NauseaGastrointestinal disorders28/27515/244
FatigueGeneral disorders22/2756/244
DiarrhoeaGastrointestinal disorders20/2759/244
HeadacheNervous system disorders17/27510/244
CoughRespiratory, thoracic and mediastinal disorders17/2756/244
InsomniaPsychiatric disorders14/2759/244

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDCLate Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDCTotal
Mean44.1 ± 10.6145.5 ± 11.2544.8 ± 10.93
Gender
Gender(Participants)Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDCLate Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDCTotal
Female383270
Male237212449
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDCLate Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDCTotal
African American/African Heritage8163144
American Indian or Alaska Native325
Asian - Central/South Asian Heritage123
Asian - East Asian Heritage134
Asian - Japanese Heritage112
Asian - South East Asian Heritage123
Asian - Mixed Race101
Native Hawaiian or other Pacific Islander112
White - Arabic/North African Heritage202
White - White/Caucasian/European Heritage176165341
White - Mixed Race336
White - Asian112
Mixed Race112
Missing202
08

Study locations

103 sites
  • GSK Investigational Site
    Phoenix, Arizona 85012, United States
  • GSK Investigational Site
    Phoenix, Arizona 85015, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90028, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90035, United States
  • GSK Investigational Site
    Los Angeles, California 90036, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Oakland, California 94602, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    San Francisco, California 94109, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    San Francisco, California 94118, United States
  • GSK Investigational Site
    San Leandro, California 94577, United States
  • GSK Investigational Site
    Torrance, California 90502, United States
  • GSK Investigational Site
    Denver, Colorado 80205-5422, United States
  • GSK Investigational Site
    Denver, Colorado 80209, United States
  • GSK Investigational Site
    Norwalk, Connecticut 06850, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20009, United States
  • GSK Investigational Site
    Washington, District of Columbia 20036, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Jacksonville, Florida 32209, United States
  • GSK Investigational Site
    Miami, Florida 33133, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Pensacola, Florida 32504, United States
  • GSK Investigational Site
    Tampa, Florida 33614, United States
  • GSK Investigational Site
    Vero Beach, Florida 32960-6571, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33401, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Atlanta, Georgia 30312, United States
  • GSK Investigational Site
    Atlanta, Georgia 30339, United States
  • GSK Investigational Site
    Augusta, Georgia 30912-3130, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Savannah, Georgia 31405, United States
  • GSK Investigational Site
    Honolulu, Hawaii 96813, United States
  • GSK Investigational Site
    Chicago, Illinois 60612-3833, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70121, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01105, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109, United States
  • GSK Investigational Site
    Berkley, Michigan 48072, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55407, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55415, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63108, United States
  • GSK Investigational Site
    St. Louis, Missouri 63110, United States
  • GSK Investigational Site
    St. Louis, Missouri 63139, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89031, United States
  • GSK Investigational Site
    Camden, New Jersey 08103, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Newark, New Jersey 07102, United States
  • GSK Investigational Site
    Santa Fe, New Mexico 87505, United States
  • GSK Investigational Site
    Bronx, New York 10467, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New York, New York 10001, United States
  • GSK Investigational Site
    Valhalla, New York 10595, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27401, United States
  • GSK Investigational Site
    Akron, Ohio 44304, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267-0405, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74127, United States
  • GSK Investigational Site
    Allentown, Pennsylvania 18102, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    Dallas, Texas 75208, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Dallas, Texas 75390-9113, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Longview, Texas 75605, United States
  • GSK Investigational Site
    Annandale, Virginia 22003, United States
  • GSK Investigational Site
    Lynchburg, Virginia 24501, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Calgary, Alberta T2R 0X7, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2T1, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8W 1M8, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Toronto, Ontario M4T 3A7, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 5B1, Canada
  • GSK Investigational Site
    Montreal, Quebec H3A 1T1, Canada
  • GSK Investigational Site
    Ponce, 00717-1567, Puerto Rico

Showing the first 100 of 103 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, Koteff JA, Wynne B, Hopking J, Granier C, Aboud M. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017;22(4):295-305. doi: 10.3851/IMP3166. Epub 2017 Apr 12. Erratum In: Antivir Ther. 2017;22(5):459-460. doi: 10.3851/IMP3192. PubMed 28401876 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Apr 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2014
First posted
Apr 7, 2014
Start
Apr 2014
Primary completionActual
Apr 2015
CompletionActual
Dec 2015
Results first posted
Feb 25, 2016
Last update
Jan 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02105987
Lead sponsor
ViiV Healthcare
Collaborators
PPD DEVELOPMENT, LP, GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 7, 2014
Start date
Apr 2014
Primary completion
Apr 2015
Completion
Dec 2015
Results posted
Feb 25, 2016
Last update
Jan 4, 2017

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dolutegravir · Lamivudine

Start the discussion